



Nemophilosides A–I, nine meroterpenoid glucosides isolated from *Nemophila menziesii*


Nanami Kurosawa¹ · Yoshinobu Ishikawa² · Tatsuo Katagiri³ · Eri Isowaki⁴ · Hayato Sato⁴ · Kenroh Sasaki¹ · Toshihiro Murata¹

Received: 22 July 2025 / Accepted: 15 October 2025 / Published online: 29 December 2025
 © The Author(s) 2025

Abstract

Nine previously undescribed meroterpenoid glucosides, named nemophilosides A–I, were isolated from the whole plant extract of *Nemophila menziesii*. Their molecular structures were determined from their NMR and MS spectra, and the absolute configurations were confirmed using ECD spectroscopy by comparing the experimental data with calculated data. The meroterpenoids consist of monoterpenoids and hydroquinone moieties; however, meroterpenoids obtained as glucosides are relatively rare, which distinguishes this class of compounds. Their skeletons are similar to those of cannabinoids and shikonins, suggesting homologous biosynthetic pathways. Compared with the well-known meroterpenoids, the monoterpenoid moieties of the compounds isolated in this study were characterized by oxidation. Although these compounds showed little or no inhibitory activity against fatty acid amide hydrolase and acetylcholinesterase, compound **6** regulated NO production in RAW264.7 cells.

Graphical Abstract



Keywords Meroterpenoid glucoside · *Nemophila menziesii* · Boraginaceae · Nemophilosides A–I · NO production in RAW264.7 cells

Introduction

Nemophila menziesii Hook. et Arn. (Boraginaceae), named baby blue eye, is an annual herb often used for ornamental purposes. Although native to North America, the blue flowers of the cultivar “Insignis Blue” are popular in gardens and parks worldwide. *Nemophila menziesii* is not commonly used for medicinal or culinary purposes despite several reports regarding the presence of a blue flower pigment [1]. In this study, we attempted to isolate meroterpenoids from the whole plant of *Nemophila menziesii*. Meroterpenoids are complexes of terpenoids and other biosynthetic products isolated from plants, fungi, and marine products, and exhibit diverse and potent biological activities; they are expected to show potential as pharmaceutical seeds, as many meroterpenoids, including cannabinoids and shikonins, have had a positive impact on society and are considered useful plant constituents [2]. The family Boraginaceae is recognized as one of the plant families that biosynthesize quinone-type meroterpenoids, with many characteristic meroterpenoids identified from the genus *Lithospermum*, [2] *Cordia*, [3] and *Arnebia*. [4] In this study, a series of significant meroterpenoids with quinone moiety, given their biosynthesis pathway, were isolated from the whole plant of *N. menziesii* (Insignis Blue). Notably, the meroterpenoids were isolated as

glucoside types on the quinone. The procedures used to determine the chemical structure of meroterpenoids from this plant are described below.

Results and discussion

The acetone–water (4:1) extract (116 g) of the whole plants of *Nemophila menziesii* Hook. et Arn. was subjected to a Diaion HP-20 column to yield approximately separated fractions Frs. 1A–1G using a methanol–water mobile phase solvent system. Compounds **1–9** were isolated from Frs. 1C [MeOH: water (2:3)] and 1D [MeOH: water (3:2)] using reversed-phase HPLC. Compounds **1–9** comprised a hydroquinone, monoterpene, and either one or two glucosyl moieties (Fig. 1).

The HPLC sugar analyses after acid hydrolysis of **1–9** showed that the glucosyl moieties were D-glucose [5], and the coupling constant value $J = 7.0\text{--}7.5$ Hz indicated their β -orientations. That is, **1–9** were meroterpenoids characterized as di- or mono-glycosides according to the number of β -D-glucosyl moieties.

The molecular formula of **1** ($\text{C}_{28}\text{H}_{36}\text{O}_{13}$) was confirmed by (+)-HRFABMS ($[\text{M} + \text{Na}]^+$ ion at m/z 603.2042, calculated for $\text{C}_{28}\text{H}_{36}\text{O}_{13}\text{Na}$: 603.2053). The ^1H and ^{13}C NMR data for **1** are listed in Table 1. In the ^1H NMR spectrum of **1**, three methyl [δ_{H} 2.24 (3H, s, H-10'), 1.56 (3H, s, H-9'),

Fig. 1 Chemical structures of meroterpenoids isolated from *Nemophila menziesii*




Table 1 MR Spectroscopic Data for Compounds **1–9**

1^a					
Position	δ_C	type	δ_H (<i>J</i> in Hz)	HMBC (H to C)	NOESY (H to H)
1	148.9	C			
2	131.5	C			
3	142.0	C			
4	151.1	C			
5	113.5	CH	6.93, d (9.0)	1, 3, 7'	6, 4- <i>O</i> -Glc-1
6	115.9	CH	7.06, d (9.0)	2, 4	5, 1- <i>O</i> -Glc-1
1'	130.6	C			
2'	127.8	CH	7.95, s	2, 4', 5', 6', 10'	10'
3'	123.9	C			
4'	156.2	C			
5'	109.0	CH	6.77, s	1', 3', 4', 7', 10'	8', 9'
6'	154.9	C			
7'	49.0 ^b	C			
8'	25.6	CH ₃	1.50, s	3, 6', 7', 9'	5'
9'	25.8	CH ₃	1.56, s	3, 6', 7', 8'	5'
10'	16.6	CH ₃	2.24, s	2', 3', 4'	2'
1- <i>O</i> -Glc-1	102.3	CH	5.07, d (7.5)	1	6, 1- <i>O</i> -Glc-2
1- <i>O</i> -Glc-2	75.3	CH	3.64, dd (9.0, 8.0)	1- <i>O</i> -Glc-1, 1- <i>O</i> -Glc-3	1- <i>O</i> -Glc-1
1- <i>O</i> -Glc-3	78.8	CH	3.35–3.55 ^b		
1- <i>O</i> -Glc-4	71.5	CH	3.35–3.55 ^b		
1- <i>O</i> -Glc-5	78.2	CH	3.35–3.55 ^b		
1- <i>O</i> -Glc-6	62.6	CH ₂	3.71, dd (11.5, 5.0)	1- <i>O</i> -Glc-5	1- <i>O</i> -Glc-6
			3.92 ^b	1- <i>O</i> -Glc-4	1- <i>O</i> -Glc-6
4- <i>O</i> -Glc-1	102.1	CH	4.99, d (7.5)	4	5
4- <i>O</i> -Glc-2	75.3	CH	3.35–3.55 ^b		
4- <i>O</i> -Glc-3	78.7	CH	3.35–3.55 ^b		
4- <i>O</i> -Glc-4	71.4	CH	3.35–3.55 ^b		
4- <i>O</i> -Glc-5	78.1	CH	3.35–3.55 ^b		
4- <i>O</i> -Glc-6	62.6	CH ₂	3.71, dd (11.5, 5.0)	4- <i>O</i> -Glc-5	4- <i>O</i> -Glc-6
			3.92 ^b	4- <i>O</i> -Glc-4	4- <i>O</i> -Glc-6
2^a					
Position	δ_C	type	δ_H (<i>J</i> in Hz)	HMBC (H to C)	NOESY (H to H)
1	149.1	C			
2	131.5	C			
3	143.0	C			
4	150.9	C			
5	113.6	CH	6.93, d (9.0)	1, 3	6, 4- <i>O</i> -Glc-1
6	115.6	CH	7.04, d (9.0)	2, 4	5, 1- <i>O</i> -Glc-1
1'	132.2	C			
2'					
	118.8	CH	7.55, s		
3'	125.2	C			
4'	143.7	C			
5'	143.0	C			
6'	138.3	C			

Table 1 (continued)

2^a					
Position	δ_C	type	δ_H (<i>J</i> in Hz)	HMBC (H to C)	NOESY (H to H)
7'	49.6 ^b	C			
8'	22.6	CH ₃	1.67, s	3, 6', 7', 9'	
9'	22.5	CH ₃	1.73, s	3, 6', 7', 8'	
10'	16.8	CH ₃	2.27, s	2', 3', 4'	
1- <i>O</i> -Glc-1	102.3	CH	5.07, d (7.5)	1	6
1- <i>O</i> -Glc-2	75.4	CH	3.63, dd (9.0, 8.0)	1- <i>O</i> -Glc-1, 1- <i>O</i> -Glc-3	
1- <i>O</i> -Glc-3	78.8	CH	3.44 ^b		
1- <i>O</i> -Glc-4	71.6	CH	3.44 ^b		
1- <i>O</i> -Glc-5	78.2	CH	3.44 ^b		
1- <i>O</i> -Glc-6	62.7	CH ₂	3.69 ^b		1- <i>O</i> -Glc-6
			3.89 ^b	1- <i>O</i> -Glc-4	1- <i>O</i> -Glc-6
4- <i>O</i> -Glc-1	102.0	CH	4.99, d (7.5)	4	5
4- <i>O</i> -Glc-2	75.3	CH	3.54, dd (9.0, 7.5)	4- <i>O</i> -Glc-1, 4- <i>O</i> -Glc-3	
4- <i>O</i> -Glc-3	78.7	CH	3.44 ^b		
4- <i>O</i> -Glc-4	71.4	CH	3.44 ^b		
4- <i>O</i> -Glc-5	78.1	CH	3.44 ^b		
4- <i>O</i> -Glc-6	62.6	CH ₂	3.69 ^b		4- <i>O</i> -Glc-6
			3.89 ^b	4- <i>O</i> -Glc-4	4- <i>O</i> -Glc-6
3^a					
Position	δ_C	type	δ_H (<i>J</i> in Hz)	HMBC (H to C)	NOESY (H to H)
1	151.6	C			
2	136.2	C			
3	121.9	CH	6.99, d (3.0)	1, 5, 1'	2', 4- <i>O</i> -Glc-1
4	154.4	C			
5	116.4	CH	6.94, dd (9.0, 3.0)	1, 3, 4	6, 4- <i>O</i> -Glc-1
6	118.5	CH	7.04, d (9.0)	1, 2, 4	5, 1- <i>O</i> -Glc-1
1'	34.3	CH	4.35, brt (4.5)	2, 2', 3'	2', 6', 8'
2'	127.5	CH	5.39, brd (5.0)	4', 6', 10'	3, 1', 10'
3'	134.1	C			
4'	32.4	CH ₂	2.20, m	3', 6'	10'
5'	21.2	CH ₂	1.65–1.95 ^b		
6'	52.0	CH	1.92, ddd (13.0, 4.5, 2.5)	2, 5', 7'	1', 8', 9'
7'	74.3	C			
8'	25.1	CH ₃	0.69, s	6', 7', 9'	1', 6', 9'
9'	29.9	CH ₃	1.00, s	6', 7', 8'	5', 6', 8'
10'	23.6	CH ₃	1.72, s	2', 3', 4'	2', 4'
1- <i>O</i> -Glc-1	104.3	CH	4.85, d (7.0)	1	6
1- <i>O</i> -Glc-2	74.9	CH	3.3–3.5 ^b		
1- <i>O</i> -Glc-3	78.2	CH	3.3–3.5 ^b		
1- <i>O</i> -Glc-4	71.3	CH	3.3–3.5 ^b		
1- <i>O</i> -Glc-5	78.0	CH	3.3–3.5 ^b		
1- <i>O</i> -Glc-6	62.6	CH ₂	3.74, dd (12.0, 5.0)		1- <i>O</i> -Glc-6
			3.85, brd (12.0)	1- <i>O</i> -Glc-4	1- <i>O</i> -Glc-6
4- <i>O</i> -Glc-1	103.3	CH	4.72, d (7.5)	4	3, 5
4- <i>O</i> -Glc-2	74.8	CH	3.3–3.5 ^b		

Table 1 (continued)

3^a					
Position	δ_C	type	δ_H (<i>J</i> in Hz)	HMBC (H to C)	NOESY (H to H)
4- <i>O</i> -Glc-3	78.1	CH	3.3–3.5 ^b		
4- <i>O</i> -Glc-4	71.1	CH	3.3–3.5 ^b		
4- <i>O</i> -Glc-5	78.0	CH	3.3–3.5 ^b		
4- <i>O</i> -Glc-6	62.3	CH ₂	3.70, dd (12.0, 5.0) 3.85, brd (12.0)	4- <i>O</i> -Glc-4	4- <i>O</i> -Glc-6 4- <i>O</i> -Glc-6
4^a					
Position	δ_C	type	δ_H (<i>J</i> in Hz)	HMBC (H to C)	NOESY (H to H)
1	151.8	C			
2	134.8	C			
3	121.9	CH	6.97, d (3.0)	1, 4, 5, 1'	2', 4- <i>O</i> -Glc-1
4	154.2	C			
5	116.5	CH	6.93, dd (9.0, 3.0)	3	6, 4- <i>O</i> -Glc-1
6	118.5	CH	7.22, d (9.0)	1, 2, 3, 4, 1'	5, 1- <i>O</i> -Glc-1
1'	34.3	CH	4.32, m	1, 2, 3, 2'	2', 6', 9'
2'	127.1	CH	5.35, brd, (5.5)	4', 6', 10'	3, 1', 10'
3'	134.4	C			
4'	32.4	CH ₂	2.10–2.25 ^b	2', 5', 6'	5', 10'
5'	21.1	CH ₂	1.60–1.90 ^b		4'
6'	51.9	CH	1.94, ddd (13.0, 4.5, 2.0)	2, 1', 5', 7', 8', 9'	1', 8', 9'
7'	74.4	C			
8'	28.7	CH ₃	0.94, s	6', 7', 9'	6', 9'
9'	26.1	CH ₃	0.77, s	6', 7', 8'	1', 6', 8'
10'	23.6	CH ₃	1.73, s	2', 3', 4'	2', 4'
1- <i>O</i> -Glc-1	104.4	CH	4.78, d (7.0)	1, 1- <i>O</i> -Glc-5	6
1- <i>O</i> -Glc-2	75.1	CH	3.39–3.45 ^b		
1- <i>O</i> -Glc-3	78.4	CH	3.39–3.45 ^b		
1- <i>O</i> -Glc-4	71.3	CH	3.39–3.45 ^b		
1- <i>O</i> -Glc-5	78.1	CH	3.39–3.45 ^b		
1- <i>O</i> -Glc-6	62.7	CH ₂	3.74, dd (12.0, 5.0) 3.70, dd (12.0, 5.0)	1- <i>O</i> -Glc-5 1- <i>O</i> -Glc-5	
4- <i>O</i> -Glc-1	102.6	CH	4.78, d (7.0)	4, 4- <i>O</i> -Glc-5	3
4- <i>O</i> -Glc-2	74.8	CH	3.39–3.45 ^b		
4- <i>O</i> -Glc-3	78.3	CH	3.39–3.45 ^b		
4- <i>O</i> -Glc-4	71.1	CH	3.39–3.45 ^b		
4- <i>O</i> -Glc-5	78.0	CH	3.39–3.45 ^b		
4- <i>O</i> -Glc-6	62.3	CH ₂	3.92, dd (12.0, 2.0) 3.84, dd (12.0, 2.0)	4- <i>O</i> -Glc-5 4- <i>O</i> -Glc-5	
5^a					
Position	δ_C	type	δ_H (<i>J</i> in Hz)	HMBC (H to C)	NOESY (H to H)
1	150.7	C			
2	135.0	C			
3	117.9	CH	6.50, d (3.0)	1, 4, 5, 1'	

Table 1 (continued)

5^a					
Position	δ_C	type	δ_H (<i>J</i> in Hz)	HMBC (H to C)	NOESY (H to H)
4	153.4	C			
5	114.7	CH	6.53, dd (8.5, 3.0)	1, 3, 4	6
6	120.4	CH	6.93, d (8.5)	1, 2, 4	5
1'	37.5	CH	4.38, brdd (5.5, 5.0)	1, 2, 3, 2', 3', 5', 6'	2', 6', 9'
2'	130.5	CH	5.61, dd (5.0, 1.0)	1', 4', 6', 10'	1', 10'
3'	135.2	C			
4'	69.2	CH	4.12, brd (3.0)	2', 3', 6'	5', 6', 10'
5'	34.0	CH ₂	2.15, dt (14.0, 5.0) 1.64 ^b	1', 6' 1', 3', 4', 6'	4', 5', 6', 8' 4', 5', 6', 8'
6'	40.3	CH	2.80, ddd (13.5, 5.0, 2.5)	2, 1', 4', 5', 7', 8', 9'	1', 4', 5', 8'
7'	149.5	C			
8'	110.5	CH ₂	4.28, s 4.50, s	6', 7', 9' 6', 7', 9'	5', 6', 8', 9' 8', 9'
9'	23.6	CH ₃	1.66, s	6', 7', 8'	1', 8'
10'	21.4	CH ₃	1.87, s	2', 3', 4'	2', 4'
1- <i>O</i> -Glc-1	105.6	CH	4.65, d (7.5)	1	6
1- <i>O</i> -Glc-2	75.2	CH	3.3–3.45 ^b		
1- <i>O</i> -Glc-3	78.3	CH	3.3–3.45 ^b		
1- <i>O</i> -Glc-4	71.7	CH	3.3–3.45 ^b		
1- <i>O</i> -Glc-5	78.1	CH	3.25, m		
1- <i>O</i> -Glc-6	62.9	CH ₂	3.67, dd (12.0, 5.0) 3.84, dd (12.0, 2.5)	1- <i>O</i> -Glc-5 1- <i>O</i> -Glc-4	1- <i>O</i> -Glc-6 1- <i>O</i> -Glc-6
4- <i>O</i> -Glc-1					
4- <i>O</i> -Glc-2					
4- <i>O</i> -Glc-3					
4- <i>O</i> -Glc-4					
4- <i>O</i> -Glc-5					
4- <i>O</i> -Glc-6					
6^a					
Position	δ_C	type	δ_H (<i>J</i> in Hz)	HMBC (H to C)	NOESY (H to H)
1	152.2	C			
2	133.6	C			
3	119.1	CH	6.89, d (3.0)	1, 5, 1'	1', 2', 4- <i>O</i> -Glc-1
4	154.4	C			
5	115.7	CH	6.87, br s	1, 3	6, 4- <i>O</i> -Glc-1
6	117.7	CH	7.08, d (9.0)	1, 2, 3, 4, 5,	5, 1- <i>O</i> -Glc-1
1'	29.2	CH ₂	3.3–3.5 ^b	1, 2, 3, 2', 3'	3, 2', 9'
2'	124.6	CH	5.39, dd (7.5, 6.0)	2, 1', 4', 9'	3, 1', 4'
3'	136.4	C			
4'	39.4	CH ₂	2.18, br t (7.5)	2', 3', 5', 6', 9'	2', 5', 6', 9'
5'	28.2	CH ₂	2.34, brdd (14.0, 7.5)	3', 4', 6', 7'	4', 6', 9', 10'
6'	143.7	CH	6.78, m	4', 5', 7', 8', 10'	4', 5'
7'	128.9	C			
8'	171.7	C			
9'	16.2	CH ₃	1.74, s	2', 3', 4'	1', 4', 5'

Table 1 (continued)

6^a					
Position	δ_C	type	δ_H (<i>J</i> in Hz)	HMBC (H to C)	NOESY (H to H)
10'	12.5	CH ₃	1.80, s	6', 7', 8'	5'
1- <i>O</i> -Glc-1	103.6	CH	4.79 ^b	1	6
1- <i>O</i> -Glc-2	75.1	CH	3.3–3.5 ^b		
1- <i>O</i> -Glc-3	78.3	CH	3.3–3.5 ^b		
1- <i>O</i> -Glc-4	71.5	CH	3.3–3.5 ^b		
1- <i>O</i> -Glc-5	78.1	CH	3.3–3.5 ^b		
1- <i>O</i> -Glc-6	62.6	CH ₂	3.70, dd (12.0, 3.0) 3.87, dd (12.0, 3.0)	1- <i>O</i> -Glc-5 1- <i>O</i> -Glc-4	1- <i>O</i> -Glc-6 1- <i>O</i> -Glc-6
4- <i>O</i> -Glc-1	103.0	CH	4.79 ^b	4	3,5
4- <i>O</i> -Glc-2	74.9	CH	3.3–3.5 ^b		
4- <i>O</i> -Glc-3	78.3	CH	3.3–3.5 ^b		
4- <i>O</i> -Glc-4	71.4	CH	3.3–3.5 ^b		
4- <i>O</i> -Glc-5	78.0	CH	3.3–3.5 ^b		
4- <i>O</i> -Glc-6	62.5	CH ₂	3.70, dd (12.0, 3.0) 3.87, dd (12.0, 3.0)	4- <i>O</i> -Glc-5 4- <i>O</i> -Glc-4	1- <i>O</i> -Glc-6 1- <i>O</i> -Glc-6
7^a					
Position	δ_C	type	δ_H (<i>J</i> in Hz)	HMBC (H to C)	NOESY (H to H)
1	151.7	C			
2	130.0	C			
3	115.4	CH	7.27, d (3.0)	1, 4, 5, 1'	2', 4- <i>O</i> -Glc-1
4	154.8	C			
5	117.9	CH	6.96, dd (9.0, 3.0)	1, 3, 4	6, 4- <i>O</i> -Glc-1
6	119.1	CH	7.13, d (9.0)	1, 2, 4, 5	5, 1- <i>O</i> -Glc-1
1'	122.6	CH	7.02, d (16.5)	1, 3, 3'	9'
2'	138.6	CH	6.27, d (16.5)	2, 3', 9'	3, 4', 9'
3'	74.2	C			
4'	44.0	CH ₂	1.60, t (6.0)	2', 3', 6'	2', 5', 6', 9'
5'	24.0	CH ₂	2.06, m	4', 6', 7'	4', 9', 10'
6'	125.8	CH	5.13, dd (8.5, 7.0)	8', 10'	4', 8', 10'
7'	132.2	C			
8'	25.9	CH ₃	1.66, s	6', 7', 10'	6'
9'	28.2	CH ₃	1.35, s	2', 3', 4'	1', 2', 4', 5'
10'	17.8	CH ₃	1.60, s	6', 7', 8'	5', 6'
1- <i>O</i> -Glc-1	103.9	CH	4.76, d (7.5)	1	6
1- <i>O</i> -Glc-2	75.1	CH	3.37–3.45 ^b		
1- <i>O</i> -Glc-3	78.3	CH	3.37–3.45 ^b		
1- <i>O</i> -Glc-4	71.4	CH	3.37–3.45 ^b		
1- <i>O</i> -Glc-5	78.1	CH	3.37–3.45 ^b		
1- <i>O</i> -Glc-6	62.6	CH ₂	3.69, dd (11.5, 5.0) 3.88, m	1- <i>O</i> -Glc-5 1- <i>O</i> -Glc-4	1- <i>O</i> -Glc-6 1- <i>O</i> -Glc-6
4- <i>O</i> -Glc-1	103.4	CH	4.80, d (7.0)	4	3, 5
4- <i>O</i> -Glc-2	75.0	CH	3.37–3.45 ^b		
4- <i>O</i> -Glc-3	78.2	CH	3.37–3.45 ^b		
4- <i>O</i> -Glc-4	71.5	CH	3.37–3.45 ^b		
4- <i>O</i> -Glc-5	78.1	CH	3.37–3.45 ^b		

Table 1 (continued)

7^a					
Position	δ_C	type	δ_H (<i>J</i> in Hz)	HMBC (H to C)	NOESY (H to H)
4- <i>O</i> -Glc-6	62.6	CH ₂	3.69, dd (11.5, 5.0) 3.88, m	4- <i>O</i> -Glc-5 4- <i>O</i> -Glc-4	4- <i>O</i> -Glc-6 4- <i>O</i> -Glc-6
8^a					
Position	δ_C	type	δ_H (<i>J</i> in Hz)	HMBC (H to C)	NOESY (H to H)
1	151.2	C			
2	130.2	C			
3	115.4	CH	7.29, d (3.0)	1, 4, 5, 1'	2', 4- <i>O</i> -Glc-1
4	154.7	C			
5	117.7	CH	6.94, dd (9.0, 3.0)	1, 3, 4	6, 4- <i>O</i> -Glc-1
6	118.8	CH	7.10, d (9.0)	1, 2, 4, 5, 1'	5, 1- <i>O</i> -Glc-1
1'	127.0	CH	6.92, d (16.0)	1, 2, 3, 3'	3, 3'
2'	134.3	CH	6.03, dd (16.0, 9.0)	2, 3', 4', 9'	3, 3', 4', 9'
3'	47.1	CH	2.36, m		1', 2', 4', 9'
4'	32.6	CH ₂	1.37, m 1.55 ^b	3', 6' 6'	2', 4', 5' 3', 4', 5', 9', 10'
5'	26.8	CH ₂	2.01, m	3', 4', 6', 7'	3', 4', 6', 10'
6'	125.7	CH	5.13, t (8.0)	8', 10'	5', 8'
7'	132.5	C			
8'	26.0	CH ₃	1.68, s	6', 7', 10'	6'
9'	66.9	CH ₂	3.54, t (6.5)	2', 3', 4'	2', 3', 4'
10'	18.0	CH ₃	1.59, s	6', 7', 8'	4', 5'
1- <i>O</i> -Glc-1	103.5	CH	4.79, d (7.0)	1, 1- <i>O</i> -Glc-5	6
1- <i>O</i> -Glc-2	75.1	CH	3.37–3.44 ^b		
1- <i>O</i> -Glc-3	78.2	CH	3.37–3.44 ^b		
1- <i>O</i> -Glc-4	71.5	CH	3.37–3.44 ^b		
1- <i>O</i> -Glc-5	78.1	CH	3.37–3.44 ^b		
1- <i>O</i> -Glc-6	62.6	CH ₂	3.69, dd (12.0, 5.0) 3.87, dd (12.0, 2.0)	1- <i>O</i> -Glc-5 1- <i>O</i> -Glc-4	1- <i>O</i> -Glc-6 1- <i>O</i> -Glc-6
4- <i>O</i> -Glc-1	103.4	CH	4.79, d (7.0)	4, 4- <i>O</i> -Glc-5	3, 5
4- <i>O</i> -Glc-2	75.0	CH	3.37–3.44 ^b		
4- <i>O</i> -Glc-3	78.2	CH	3.37–3.44 ^b		
4- <i>O</i> -Glc-4	71.4	CH	3.37–3.44 ^b		
4- <i>O</i> -Glc-5	78.1	CH	3.37–3.44 ^b		
4- <i>O</i> -Glc-6	62.6	CH ₂	3.69, dd (12.0, 5.0) 3.87, dd (12.0, 2.0)	4- <i>O</i> -Glc-5 4- <i>O</i> -Glc-4	4- <i>O</i> -Glc-6 4- <i>O</i> -Glc-6
9^a					
Position	δ_C	type	δ_H (<i>J</i> in Hz)	HMBC (H to C)	NOESY (H to H)
1	151.2	C			
2	130.2	C			
3	115.3	CH	7.30, d (3.0)	1, 4, 5, 1'	2', 4- <i>O</i> -Glc-1
4	154.7	C			
5	117.8	CH	6.94, dd (9.0, 3.0)	1, 2, 3, 4	6, 4- <i>O</i> -Glc-1

Table 1 (continued)

9^a					
Position	δ_C	type	δ_H (J in Hz)	HMBC (H to C)	NOESY (H to H)
6	118.9	CH	7.11, dd (9.0)	1, 2, 4, 5, 1'	5, 1- <i>O</i> -Glc-1
1'	127.1	CH	6.87, d (18.0)	1, 2, 3, 4, 3'	3'
2'	134.1	CH	6.03, dd (16.0, 9.0)	2, 3', 4', 9'	3, 9'
3'	47.0	CH	2.35, m		1', 4', 9'
4'	32.7	CH ₂	1.39, m	3', 6'	4', 5'
			1.59, m		3', 4', 9'
5'	26.3	CH ₂	2.10, t (7.5)	4', 6', 7'	4', 6', 10'
6'	128.9	CH	5.29, t (6.0)	4', 5', 8', 10'	4', 5', 8'
7'	136.0	C			
8'	21.6	CH ₃	1.76, s	6', 7', 10'	6', 10'
9'	66.9	CH ₂	3.53, dd (6.0, 2.5)	2', 3', 4'	2', 3', 4'
10'	61.6	CH ₂	4.02, m	6', 7', 8'	5', 8'
1- <i>O</i> -Glc-1	103.5	CH	4.80, d (7.5)	1, 1- <i>O</i> -Glc-5	6
1- <i>O</i> -Glc-2	75.1	CH	3.35–3.45 ^b		
1- <i>O</i> -Glc-3	78.3	CH	3.35–3.45 ^b		
1- <i>O</i> -Glc-4	71.6	CH	3.35–3.45 ^b		
1- <i>O</i> -Glc-5	78.1	CH	3.35–3.45 ^b		
1- <i>O</i> -Glc-6	62.6	CH ₂	3.68, dd (12.0, 5.5)		1- <i>O</i> -Glc-6
			3.85, dd (14.0, 3.0)		1- <i>O</i> -Glc-6
4- <i>O</i> -Glc-1	103.4	CH	4.80, d (7.5)	4, 4- <i>O</i> -Glc-5	3, 5
4- <i>O</i> -Glc-2	75.0	CH	3.35–3.45 ^b		
4- <i>O</i> -Glc-3	78.2	CH	3.35–3.45 ^b		
4- <i>O</i> -Glc-4	71.4	CH	3.35–3.45 ^b		
4- <i>O</i> -Glc-5	78.0	CH	3.35–3.45 ^b		
4- <i>O</i> -Glc-6	62.5	CH ₂	3.68, dd (12.0, 5.5)		4- <i>O</i> -Glc-6
			3.85, dd (14.0, 3.0)		4- <i>O</i> -Glc-6

^aIn methanol-*d*₄ solution^bUnclear signal pattern due to overlapping

and 1.50 (3H, s, H-8'), olefinic [δ_H 7.95 (1H, s, H-2'), 7.06 (1H, d, $J=9.0$ Hz, H-6), 6.93 (1H, d, $J=9.0$ Hz, H-5), and 6.77 (1H, s, H-5') and glycosyl [δ_H 5.07–3.35] proton resonances were observed. In the aliphatic region of the ¹³C NMR spectrum of **1**, three methyl (δ_C 25.8, C-9'; 25.6, C-8'; 16.6, C-10'), one quaternary (δ_C 49.0, overlapping, C-7'), and two sets of glucosyl (δ_C 102.3, 75.3, 78.8, 71.5, 78.2, 62.6 and δ_C 102.1, 75.3, 78.7, 71.4, 78.1, 62.6) carbon resonances were observed. In its olefinic region, there were 12 carbon resonances indicating the presence of two phenyl moieties (δ_C 148.9, C-1; 131.5, C-2; 142.0, C-3; 151.1, C-4; 113.5, C-5; 115.9, C-6; 130.6, C-1'; 127.8, C-2'; 123.9, C-3'; 156.2, C-4'; 109.0, C-5'; 154.9, C-6'). In the HMBC spectrum, two methyl (H-8' and H-9') and H-5' protons were long-range coupled with the quaternary C-7'; the methyl protons and H-5 were long-range coupled with C-3, which suggested the two phenyl moieties were connected to the

quaternary carbon. The HMBC correlations from the other methyl and olefinic protons (Fig. 2) suggested the presence of the 3',7',7'-tri-methyl-1,4,4'-trioxy-fluorene skeleton. The NOESY correlation between H-2' and H-10' and that between H-5' and H-8' supported this conclusion. The anomeric protons at δ_H 5.07 (1H, d, $J=7.5$ Hz) and 4.99 (1H, d, $J=7.5$ Hz) were HMBC long-range coupled with C-1 and C-4, respectively, which showed the 1,4-diglucosyl of fluorene. From these data, the chemical structure of **1** was established as illustrated in Fig. 1.

Compound **2** had a molecular formula of C₂₈H₃₆O₁₄ (HRFABMS negative m/z 595.2042; [M-H][−] ion at m/z , calcd for C₂₈H₃₅O₁₄: 595.2027), with one more oxygen atom than that in **1**. There is no H-5' resonance in the ¹H NMR spectrum, and an oxygenated olefinic carbon (δ_C 143.0, C-5') was observed in the ¹³C NMR spectrum of **2**, instead




Fig. 2 Key HMBC and NOE correlations of compounds **1–9**

of δ_{C} 109.0 in that of **1**. Therefore, **2** was confirmed to be a hydroxy derivative of **1** as shown in Fig. 1.

The molecular formula of **3** ($\text{C}_{28}\text{H}_{42}\text{O}_{13}$) was confirmed using (+)-HRFABMS, which showed an $[\text{M} + \text{Na}]^+$ ion at m/z 609.2515 (calcd. for $\text{C}_{28}\text{H}_{42}\text{O}_{13}\text{Na}$: 609.2523). The ^1H

NMR spectrum of **3** showed three methyl [δ_{H} 1.72 (3H, s, H-10'), 1.00 (3H, s, H-9'), and 0.69 (3H, s, H-8')], *o*- and *m*-coupling system olefinic [δ_{H} 6.99 (1H, d, $J=3.0$ Hz, H-3), 6.94 (1H, dd, $J=9.0, 3.0$ Hz, H-5), 7.04 (1H, d, $J=9.0$ Hz, H-6)] proton resonances were observed. In the ^{13}C NMR

spectrum, 12 glycosidic, 10 terpenoid, and six phenyl carbon resonances were observed. These data, except for that of the sugar moieties were similar to those of conitriol which was one of the meroterpenoids isolated from the Ascidian *Aplidium conicum*. [6] The HMBC correlations (Fig. 2), including those from H-10' to C-2' (δ_C 127.5), C-3' (δ_C 134.1), C-4' (δ_C 32.4); from H-8' and H-9' to C-6' (δ_C 52.0); from H-3 to C-1 (δ_C 151.6), C-5 (δ_C 116.4), C-1' (δ_C 34.3), supported that the aglycone of **3** was conitriol.

The 1,4-diglucosyl moiety was confirmed by the HMBC correlations between the anomeric protons at δ_H 4.85 (1H, d, $J=7.0$ Hz) and 4.72 (1H, d, $J=7.5$ Hz) and C-1 and C-4 (δ_C 154.4), respectively. The relative configuration of C-1' and C-6' was confirmed as the *Z*-configuration by the coupling constant $J_{1'-6'}=4.5$ Hz and the NOESY correlation, [6–8]. Based on the determined structures, the most stable conformations were calculated for all the possible absolute configurations at C-1' and C-6' on the cyclohexene ring (Figure S2). Thereafter, the dihedral diagonals were obtained

and applied to the Karplus equation ($1'S6'R$: $J_{1'-6'}=4.37$ Hz; $1'S6'S$: $J_{1'-6'}=7.61$ Hz; $1'R6'R$: $J_{1'-6'}=1.56$ Hz; $1'R6'S$: $J_{1'-6'}=3.57$ Hz), which supports its *Z*-configuration. Furthermore, their expected ECD spectra were calculated, and the C-1' absolute configuration of **3** was confirmed to be *S* by the strong negative Cotton effect at approximately 205 nm in the ECD spectrum by comparison with the calculated data and experimental data of **3** (Fig. 3A). The chemical structure of compound **3** was confirmed to be as shown in Fig. 1.

The molecular formula of **4** ($C_{28}H_{42}O_{13}$) was confirmed using (+)-HRFABMS ($[M+Na]^+$ ion at m/z 609.2515, calcd. for $C_{28}H_{42}O_{13}Na$: 609.2523), which was identical to that of **3**. The 1H and ^{13}C NMR spectra of **4** are similar to those of **3** (Table 1), suggesting that the aglycone of **4** is an enantiomer of the aglycone of **3**. In the ECD curve of **4**, a positive Cotton effect was observed at approximately 205 nm, indicating the $1'R$ -configuration (Fig. 3A). Therefore, the structure of **4** was elucidated as shown in Fig. 1.




Fig. 3 A: Experimental ECD spectra of **3–5** and calculated ECD spectra of $1'S$ -**3** and $1'R$ -**3**, B: Experimental ECD spectrum of **7** and calculated ECD spectra of $3'R$ -**7** and $3'S$ -**7** and simplified models **7a**

and **7b**, C: Experimental ECD spectrum of **8** and **9** and calculated ECD spectra of $3'R$ -**8** and $3'S$ -**8** and simplified models **8a** and **8b**

The molecular formula of **5** ($C_{22}H_{30}O_8$) was determined using (–)-HRFABMS, which showed an $[M-H]^-$ ion at m/z 421.1867 (calcd. for $C_{22}H_{29}O_8$: 421.1863). The 1H and ^{13}C NMR spectra of **5** (Table 1) were similar to those of **3** and **4**. Conversely, **5** had additional olefinic protons and carbons (δ_H 4.50, 1H, s, H-8'; 4.28, 1H, s, H-8'; δ_C 149.5, C-7'; 110.5, C-8') and an oxygenated carbon and corresponding proton resonances (δ_H 4.12, 1H, br d, $J=3.0$ Hz, H-4'; δ_C 69.2, C-4') and only one set of the glucosyl moiety. In the HMBC spectrum, H-2' (δ_H 5.61, 1H, dd, $J=5.0, 1.0$ Hz), H-6' (δ_H 2.80, 1H, ddd, $J=13.5, 5.0, 2.5$), and H-10' (δ_H 1.87, 3H, s) protons were long-range coupled with C-4', suggesting a hydroxy group bonded to C-4'. The HMBC correlations from H-8' to C-6' (δ_C 40.3), C-7', and C-9' (δ_C 23.6) indicated the C-7'–C-8' double bond. The anomeric proton resonance at δ_H 4.65 (1H, d, $J=7.5$ Hz) was long-range coupled with C-1, suggesting that the glucosyl group was bonded to C-1. The relative and absolute configurations of C-1'S and C-6'R of **5** were confirmed by the same procedure used to confirm those of **3** and **4** (Fig. 3A and Figure S2). Although it was weak, a NOESY correlation was observed between H-4' and H-6', suggesting C-4' was in the *R*-configuration. From these data, the structure of **5** was elucidated, as shown in Fig. 1.


The molecular formula of **6** ($C_{28}H_{40}O_{14}$) was confirmed by (–)-HRFABMS, which showed a $[M-H]^-$ ion at m/z 599.2323 (calcd. for $C_{28}H_{39}O_{14}$: 599.2340). The IR absorption at 1683 cm^{-1} suggested the presence of the α,β -unsaturated carboxylic acid moiety. In the 1H NMR spectrum of **6**, the proton resonances of H-3 (δ_H 6.89, 1H, d, $J=3.0$ Hz), H-5 (δ_H 6.87, 1H, br s), and H-6 (δ_H 7.08, 1H, d, $J=9.0$ Hz) indicated the presence of the 1,2,4-trisubstituted benzene. The two 3H singlet proton resonances (δ_H 1.80 and 1.74) suggested the presence of two methyl groups. In the ^{13}C NMR spectrum of **6**, a carbonyl (δ_C 171.7, C-8'), 10 olefinic (δ_C 152.2, C-1; 133.6, C-2; 119.1, C-3; 154.4, C-4; 115.7, C-5; 117.7, C-6; 124.6, C-2'; 136.4, C-3'; 143.7, C-6'; 128.9, C-7'), and 5 aliphatic (δ_C 29.2, C-1'; 39.4, C-4'; 28.2, C-5'; 16.2, C-9'; 12.5, C-10') carbon resonances were observed. The HMBC correlations from H-3 to C-1, C-5, and C-1', from H-6 to C-1, C-2, C-4, and C-5, from the two anomeric protons (δ_H 4.79, overlapping) to C-1 and C-4 indicated the 1,4-diglucosyl-2-*C*-substituted benzene moiety. Furthermore, the HMBC correlation from the two methyl groups (H-9' to C-2', C-3', C-4') and (H-10' to C-6', C-7', C-8') and from the two olefinic protons (H-2' to C-2, C-1', C-4', C-9') and (H-6' to C-4', C-5', C-7', C-8', C-10') established the structure of the side chain. The NOESY correlation between H-1' and H-9' and between H-5' and H-10' indicated a *E*-configurations of the C-2'–C-3' and the C-6'–C-7' double bonds. The data show the chemical structure of **6** (Fig. 1).

In the UV spectra of compounds **7–9**, common absorption peaks at 250–251 nm and 303–304 nm were observed,

suggesting that they had similar skeletons. Compound **7** was a prenylated phenyl glycoside, similar to **6**. Its negative-mode HRFABMS (m/z 585.2535 $[M-H]^-$, calcd for $C_{28}H_{41}O_{13}$: 585.2547) established its molecular formula as $C_{28}H_{42}O_{13}$. In the 1H NMR spectrum of **7**, one set of *E*-configured olefinic proton (δ_H 7.02, 1H, d, $J=16.5$ Hz, H-1'; 6.27, 1H, d, $J=16.5$ Hz, H-2') and three singlet methyl proton (δ_H 1.66, H-8'; 1.60, H-10'; 1.35, H-9') resonances were observed instead of those of H-1' methylene, H-2' olefinic, and two methyl protons (H-9', H-10') in **6**. The ^{13}C NMR spectrum of **7** suggested that C-8' was a methyl instead of a carbonyl as in **6**. Although it was difficult to determine the absolute configuration of C-3' owing to its chain structure and low yield, we attempted to use ECD. The experimental spectrum was compared with the calculated values of the stable conformations of each 3'*R*-**7** and 3'*S*-**7**. The negative and positive Cotton effect curves of the calculated data in the 220–240 nm and 240–300 nm ranges, respectively, were in good agreement with the experimental curves (Fig. 3B). However, the 200–220 curves conflict with each other. Therefore, ECD of the simpler modeled structures of **7** (**7a** and **7b**) were calculated (Fig. 3B) and compared with the experimental ECD spectrum of **7**; the 3'*R* calculated curves were in better agreement with the experimental curve, suggesting a 3'*R* configuration of **7**. Therefore, 250–280 nm may be a key region. (Fig. 3B and Figure S3 and S4).

The molecular formula $C_{28}H_{42}O_{13}$ of compound **8** was identical to that of **7** as obtained from HRFABMS (negative) m/z 585.2540 $[M-H]^-$ (calcd. for $C_{28}H_{41}O_{13}$: 585.2547). In the 1H NMR spectrum of **8**, methylene (δ_H 3.54, 2H, t, $J=6.5$ Hz, H-9') and methine (δ_H 2.36, 1H, m, H-3') proton resonances were observed instead of the H-9' methyl in **7**. Similar to **7**, the stable conformations of 3'*R*-**8** and 3'*S*-**8** and their ECD data were calculated and compared with the experimental ECD spectrum of **8** (Fig. 3C). The 3'*R* calculated curves were in better agreement with the experimental curve, suggesting a 3'*R* configuration of **8**. Although the calculated data of the simpler modeled structures of **8** (**8a** and **8b**) were not fully conclusive, 240–270 nm and/or 190–210 nm appeared to be the key regions (Fig. 3C).

Compound **9** showed a molecular formula of $C_{28}H_{42}O_{14}$ [HRFABMS (negative) m/z 601.2493 $[M-H]^-$ (calcd. for $C_{28}H_{41}O_{14}$: 601.2496), with one more oxygen atom than that of compound **8**. In the 1H NMR spectrum of **9**, an oxygenated methylene (δ_H 4.02, 2H, m, H-10') proton resonance was observed instead of that of the H-10' methyl as observed for **8**. The NOESY correlation between H-5' and H-10' and between H-6' and H-8' indicated a *Z*-configuration of the C-6'–C-7' double bond. The experimental ECD spectrum of **9** was similar to that of **8**, indicating its 3'*R*-configuration (Fig. 3C). From the above results, the chemical structures of **7–9** were those shown in Fig. 1.



Scheme 1 Expected biosynthetic pathway of *Nemophila* meroterpenoids compared with those of the shikonin of *Lithospermum erythrorhizon* and cannabinoids of *Cannabis sativa*

The meroterpenoids obtained in this study (1–9) are chemical structures characterized by being a hybrid of the hydroquinone moiety and the typical monoterpene moieties, including carvacrol (1 and 2), α-terpineol (3 and 4), carveol (5), and linalool (7). Compounds 6–9 have prenyl chain structures and are derivatives of geranylhydroquinone isolated from *Aplidium*; [6, 7] 6–9 are similar to the starting material for shikonins, which are the main constituents of the medicinal drug *Lithospermum* Root (*Lithospermum erythrorhizon*, Boraginaceae) [9]. Furthermore, compounds 3–5 may be applied in the order of the biosynthetic pathways of cannabinoids identified from *Cannabis sativa*, including tetrahydrocannabinol (THC) and cannabidiol (CBD) (Scheme 1). [10] Compounds 1 and 2 have a fluorene skeleton. Given their biosynthetic pathways, their structures are very similar to those of cannabinol (CBN). CBN has an ether bond with an olivetol

moiety, and it appeared that in compounds 1 and 2, the bond between C-3 and C-7' forms via a similar pathway (Scheme 1). Because CBN is easily produced via oxidation and dehydration from THC [10], it is possible that non-oxidized compounds (3a–6a) may exist in this plant. Although the specific mechanisms and enzyme involvement have not been established, compounds 1 and 2 are presumably derived from 3 and 4, while compounds 6–9 are likely derived from 6a, through a series of oxidation steps. The most important feature of *Nemophila* meroterpenoids is their glycosylated form, as such compounds are relatively rare. Second, many of them are oxidized compared with the general terpenoid moieties. Because glucosidation occurred only at the two hydroxyl groups of hydroquinone, it was assumed to be caused by hydroquinonization, and the absence of glycosylated hydroxy groups in all the obtained derivatives, except for the




Fig. 4 A: NO production from mouse RAW264.7 macrophage cells with the solutions of 1–9 and B: cytotoxicity of 1–9 against the cells. *: $p < 0.05$

Table 2 In vitro FAAH inhibitory compounds from *Nemophila menziesii*

Sample	Inhibition rate (%) ^a	IC ₅₀ (mM)
1	93.7	5.41
2	92.1	3.98
3	26.9	N.D
4	36.2	N.D
5	72.0	12.3
6	34.6	N.D
7	23.8	N.D
8	30.2	N.D
9	1.81	N.D
positive control ^b	—	0.00388

Each value was average of triplicated tests

^a1.0 mg of sample was solved in the 100 μL of DMSO

^bJZL 195 hydrochloride

hydroquinone moieties, suggested that glucosidation occurred at the 2-geranylhydroquinone stage (Scheme 1).

The above (Scheme 1) provides hints for considering the biosynthetic pathways of plants that contain meroterpenoids and should be investigated in future studies.

To investigate the biological activities of the isolated meroterpenoids, with reference to the anti-inflammatory and/or sedative effects of shikonins [11] and cannabinoids

[12] and the inhibitory activities against cholinesterase of many meroterpenoids [4], the anti-degranulation activity and toxicity to mouse RAW264.7 macrophage cells, fatty acid amide hydrolase (FAAH) inhibitory activity, and acetylcholinesterase (AChE) inhibitory activities were evaluated. Compound 6 significantly regulated nitric oxide (NO) production from the LPS-stimulated RAW264.7 cells at 100 μg/mL with no toxicity, showing inhibition of degranulation (Fig. 4).

The cytotoxicity of compound 2 may be attributed to the presence of catechol; however, the details are unknown. For the FAAH inhibitory test, the IC₅₀ values were estimated as 1, 2, and 5, and the compounds showed very low activity relative to that of the positive control JZL 195 hydrochloride (Table 2). No active compounds inhibited AChE in this study. Currently, among the *Nemophila* meroterpenoids, no significant biological activity has been revealed. One of the reasons why no strong activity was found in this study may be partly because 1–9 were all glycosides. The activities of aglycones alone or their function as glycosides in plants are issues to be addressed in future studies.

Experimental section

General experimental procedures

The optical rotations were recorded using a P-2300 polarimeter (Jasco Co., Tokyo, Japan). The UV spectra were recorded using a Shimadzu MPS-2450 instrument (Shimadzu, Kyoto, Japan). ECD spectra were recorded using a JASCO J-720 spectropolarimeter (Jasco Co.). Fluorescence detection assays were recorded using a SpectraMax® iD5 Multimode Microplate Reader (moleculardevices, Tokyo, Japan). ¹H NMR (400 MHz) and ¹³C NMR (100 MHz), ¹H-¹H COSY, HMQC (optimized for ¹J_{C-H} = 145 Hz), and HMBC (optimized for ⁿJ_{C-H} = 8 Hz) spectra were recorded on JNM-AL400, JNM-ECZ400S/L1, and JNM-ECZ600R/S1 FT-NMR spectrometers (JEOL Ltd., Tokyo, Japan) (chemical shifts are expressed in δ relative to TMS (δ 0) as the internal standard or residual solvent peaks methanol-*d*₄ (δ_H 3.305, δ_C 49.0). HR-FABMS data were obtained on a JMS700 mass spectrometer (Jeol Ltd.) using either *m*-nitrobenzyl alcohol or a glycerol matrix. A Diaion HP-20 column (Mitsubishi Chemical Co., Tokyo, Japan) was used for column chromatography. Preparative HPLC was performed on a Jasco 2089 instrument fitted with a UV detector (210 nm) [columns: TSKgel ODS-120T (Tosoh, Tokyo, Japan, 21.5 × 300 mm), TSK-gel ODS-80Ts (Tosoh, Tokyo, Japan, 21.5 × 300 mm), Develosil C₃₀-UG-5 (Nomura Chemical, Aichi, Japan, 20 × 250 mm), CAPCELL PAK C18 AQ (OSAKA SODA CO., LTD., Osaka Japan, 20 × 250 mm), COSMOSIL 5C₁₈-AR-II (NACALAI TESQUE,

INC., Kyoto, Japan, 20 × 250 mm) and ODS-SM-50C-M (Yamazen Co., Osaka, Japan, 37 × 300 mm)].

Plant material

Nemophila menziesii Hook. et Arn. (“Insignis Blue”) was harvested from the National Management Hitachi Seaside Park (605–4 Onuma-aza, Mawatari, Hitachinaka, Ibaraki 312–0012, Japan). A voucher specimen (no. TMPUNM20230530) was deposited in the herbarium of Tohoku Medical and Pharmaceutical University. One of the authors (TM) identified this plant species as previously described [13].

Extraction and isolation

The whole plant of *Nemophila menziesii* was extracted using acetone-H₂O (4:1) to obtain a crude extract (116.8 g). This crude extract was applied to a Diaion HP-20 open column, and eluted with H₂O (fraction NM-1A, 68.0 g), methanol (MeOH)-H₂O (1:4) (fraction NM-1B, 5.27 g), MeOH-H₂O (2:3) (fraction NM-1C, 2.27 g), MeOH-H₂O (3:2) (fraction NM-1D, 2.92 g), MeOH-H₂O (4:1) (fraction NM-1E, 2.39 g), MeOH (fraction NM-1F, 1.5 g) and acetone (fraction NM-1G, 0.59 g). Fraction NM-1C was subjected to a reverse-phase HPLC column ODS-SM-50C-M and eluted using a gradient system from MeOH-H₂O (1:9) to MeOH-H₂O (1:1) to yield 14 fractions (fraction NM-2A–N). Fraction 2E (437.9 mg) was subjected to HPLC separation using TSK-gel ODS-80Ts (3:17 and 1:4 CH₃CN-H₂O as the mobile phases) to yield compounds **1** (6.0 mg) and **2** (6.8 mg). Fraction 2J (39.7 mg) was subjected to HPLC separation using a TSK-gel ODS-120T column (with 1:4 CH₃CN-H₂O as the mobile phase) to yield compound **3** (5.3 mg). Fraction 2F (252.4 mg) was subjected to HPLC separation using TSK-gel ODS-80Ts (1:9, 3:17, and 1:4 CH₃CN-H₂O as the mobile phase) and CAPCELL PAK C₁₈ AQ (3:17 CH₃CN-H₂O as the mobile phase) to yield compound **9** (5.3 mg). Fraction NM-1D was subjected to HPLC separation using an ODS-SM-50C-M and eluted using a gradient system from MeOH-H₂O (3:7) to MeOH-H₂O (3:2), yielding 13 fractions (fraction NM-3A–M). Fraction 3B (231.7 mg) was subjected to HPLC separation using the TSK-gel ODS-80Ts (1:4 CH₃CN-H₂O as the mobile phase), and the COSMOSIL 5C₁₈-AR-II (1:4 CH₃CN-H₂O as the mobile phase) to yield compound **5** (1.8 mg). A mixture of fractions 3C and 3D (280.5 mg) was subjected to HPLC separation using TSK-gel ODS-80Ts (3:17, CH₃CN-H₂O as the mobile phase) and CAPCELL PAK C₁₈ AQ (1:4, CH₃CN-H₂O as the mobile phase) to yield compounds **3** (3.8 mg) and **4** (13.3 mg). A mixture of fractions 3E and 3F

(311.6 mg) was subjected to HPLC separation using a TSK-gel ODS-80Ts (1:4, CH₃CN-H₂O as the mobile phase) and CAPCELL PAK C₁₈ AQ (1:4 CH₃CN-H₂O as the mobile phase) to yield compound **6** (7.6 mg). A mixture of 3G, 3H, and 3I (321.1 mg) was subjected to HPLC separation using TSK-gel ODS-80Ts (5:15, CH₃CN-H₂O as the mobile phase), CAPCELL PAK C₁₈ AQ (3:17, CH₃CN-H₂O as the mobile phase), and TSKgel ODS-120T (1:4, CH₃CN-H₂O as the mobile phase) to yield compounds **7** (6.1 mg) and **8** (2.0 mg).

Nemophiloside A (1)

Pale brown amorphous solid; $[\alpha]_D^{21} -55$ (c 5.6, MeOH); ¹H NMR (MeOH-*d*₄, 400 MHz), Table 1; ¹³C NMR (MeOH-*d*₄, 100 MHz), Table 1; HRFABMS (positive) *m/z* 603.2042 [M + Na]⁺ (calcd for C₂₈H₃₆O₁₃Na: 603.2053); IR $\nu_{\max}$ (KBr) cm^{−1}: 3420, 2930, 1679, 1494, 1465, 1253, 1076; UV (MeOH) $\lambda_{\max}$ (log ϵ) 219 (2.94), 278 (1.27), 301 (1.12) nm.

Nemophiloside B (2)

Dark brown amorphous solid; $[\alpha]_D^{21} -83$ (c 7.1, MeOH); ¹H NMR (MeOH-*d*₄, 400 MHz), Table 1; ¹³C NMR (MeOH-*d*₄, 100 MHz), Table 1; HRFABMS (negative) *m/z* 595.2042 [M − H][−] (calcd for C₂₈H₃₅O₁₄: 595.2027); IR $\nu_{\max}$ (KBr) cm^{−1}: 3420, 2930, 1637, 1496, 1252, 1075; UV (MeOH) $\lambda_{\max}$ (log ϵ) 222 (3.02), 282. (1.72) nm.

Nemophiloside C (3)

Pale brown amorphous solid; $[\alpha]_D^{21} -136$ (c 9.2, MeOH); ¹H NMR (MeOH-*d*₄, 400 MHz), Table 1; ¹³C NMR (MeOH-*d*₄, 100 MHz), Table 1; HRFABMS (positive) *m/z* 609.2515 [M + Na]⁺ (calcd for C₂₈H₄₂O₁₃Na: 609.2523); IR $\nu_{\max}$ (KBr) cm^{−1}: 3393, 2932, 1648, 1493, 1386, 1245, 1201, 1075; UV (MeOH) $\lambda_{\max}$ (log ϵ) 218 (2.81), 283 (0.76) nm; ECD (c 0.00050, MeOH) ([θ]) 206 (−106,400), 257 (+1800), 283 (−80), 302 (+900) nm.

Nemophiloside D (4)

Yellow amorphous solid; $[\alpha]_D^{21} +42$ (c 10.3, MeOH); ¹H NMR (MeOH-*d*₄, 400 MHz), Table 1; ¹³C NMR (MeOH-*d*₄, 100 MHz), Table 1; HRFABMS (positive) *m/z* 609.2515 [M + Na]⁺ (calcd for C₂₈H₄₂O₁₃Na: 609.2523); IR $\nu_{\max}$ (KBr) cm^{−1}: 3402, 2934, 1652, 1492, 1388, 1244, 1201, 1075; UV (MeOH) $\lambda_{\max}$ (log ϵ) 219 (2.85), 282 (0.79), 323 (0.38) nm; ECD (c 0.00050, MeOH) ([θ]) 206 (+96,000), 280 (−400), 303 (+1200) nm.

Nemophiloside E (5)

Pale yellow amorphous solid; $[\alpha]_D^{21} -153$ (*c* 2.0, MeOH); ^1H NMR (MeOH- d_4 , 400 MHz), Table 1; ^{13}C NMR (MeOH- d_4 , 100 MHz), Table 1; HRFABMS (negative) m/z 421.1867 $[\text{M}-\text{H}]^-$ (calcd for $\text{C}_{28}\text{H}_{35}\text{O}_{14}$: 421.1863); IR ν_{max} (KBr) cm^{-1} : 3402, 2927, 1633, 1495, 1452, 1202, 1073, 1040; UV (MeOH) λ_{max} (log ϵ) 206 (1.66), 287 (0.20) nm; ECD (*c* 0.00050, MeOH) ([θ]) 207 (−108,100), 257 (+900), 286 (−1000) nm.

Nemophiloside F (6)

Pale brown amorphous solid; $[\alpha]_D^{21} -38$ (*c* 4.9, MeOH); ^1H NMR (MeOH- d_4 , 400 MHz), Table 1; ^{13}C NMR (MeOH- d_4 , 100 MHz), Table 1; HRFABMS (negative) m/z 599.2323 $[\text{M}-\text{H}]^-$ (calcd for $\text{C}_{28}\text{H}_{39}\text{O}_{14}$: 599.2340); IR ν_{max} (KBr) cm^{-1} : 3401, 2926, 1683, 1496, 1386, 1206, 1074; UV (MeOH) λ_{max} (log ϵ) 211 (2.43), 280 (0.37) nm.

Nemophiloside G (7)

Pale yellow amorphous solid; $[\alpha]_D^{21} -47$ (*c* 6.4, MeOH); ^1H NMR (MeOH- d_4 , 400 MHz), Table 1; ^{13}C NMR (MeOH- d_4 , 100 MHz), Table 1; HRFABMS (negative) m/z 585.2535 $[\text{M}-\text{H}]^-$ (calcd for $\text{C}_{28}\text{H}_{41}\text{O}_{13}$: 585.2547); IR ν_{max} (KBr) cm^{-1} : 3401, 2923, 1633, 1493, 1378, 1206, 1076; UV (MeOH) λ_{max} (log ϵ) 217 (2.82), 250 (2.09), 303 (0.66) nm; ECD (*c* 0.00050, MeOH) ([θ]) 206 (−13,900), 258 (+4900), 308 (−10), 398 (+1200) nm.

Nemophiloside H (8)

Colorless amorphous solid; $[\alpha]_D^{21} -23$ (*c* 2.3, MeOH); ^1H NMR (MeOH- d_4 , 400 MHz), Table 1; ^{13}C NMR (MeOH- d_4 , 100 MHz), Table 1; HRFABMS (negative) m/z 585.2540 $[\text{M}-\text{H}]^-$ (calcd for $\text{C}_{28}\text{H}_{41}\text{O}_{13}$: 585.2547); IR ν_{max} (KBr) cm^{-1} : 3401, 2953, 2922, 1655, 1493, 1377, 1209, 1076; UV (MeOH) λ_{max} (log ϵ) 210 (1.40), 251 (0.683), 304 (0.22) nm; ECD (*c* 0.00050, MeOH) ([θ]) 198 (−12,300), 255 (+11,700), 305 (+100), 405 (+1200) nm.

Nemophiloside I (9)

Colorless amorphous solid; $[\alpha]_D^{21} -23$ (*c* 5.3, MeOH); ^1H NMR (MeOH- d_4 , 400 MHz), Table 1; ^{13}C NMR (MeOH- d_4 , 100 MHz), Table 1; HRFABMS (negative) m/z 601.2493 $[\text{M}-\text{H}]^-$ (calcd for $\text{C}_{28}\text{H}_{41}\text{O}_{14}$: 601.2496); IR ν_{max} (KBr) cm^{-1} : 3393, 2927, 1672, 1493, 1430, 1208, 1076; UV (MeOH) λ_{max} (log ϵ) 207 (0.26), 251 (0.11), 304 (0.03) nm; ECD (*c* 0.00050, MeOH) ([θ]) 198 (−15,300), 255 (+12,400), 313 (−500), 393 (+300) nm.

Acid hydrolysis and sugar identification

Compounds **1–4**, **6**, **7**, and **9** (1.0 mg) and **5** and **8** (0.5 mg) were separately hydrolyzed with 6 N HCl (0.5 mL) at 70 °C for 1 h. The reaction mixture was filtered through an HP-20 column (5 × 50 mm) using H_2O (2 mL), and the eluted solution was concentrated. The concentrated samples were separately stirred with L-cysteine methyl ester (5 mg, respectively) in pyridine (0.5 mL) at 60 °C for 1 h, after which *o*-tolyl isothiocyanate (10 μL) was added. The mixtures were analyzed using HPLC (Thermo Acclaim C₁₈, 4.6 × 250 mm; mobile phase, $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ (1:3) containing 0.1% TFA, 1.0 mL/min; detector, UV at 256 nm). D-Glucose derivatives were detected at t_R 18.9–19.3 min by comparison with the authentic standards of D-glucose (t_R 18.9 min) and L-glucose derivatives (t_R 17.3 min), and the glycosidic moiety in **1–9** was identified as D-glucose [5].

ECD calculations

Conformational analysis was performed using a previously reported shell script [14]. More specifically, 300 energy-minimized three-dimensional structures of the stereoisomers of compounds **3**, **7**, and **8**, and 150 energy-minimized three-dimensional structures of the simplified model structures of **7** (**7a** and **7b**) and **8** (**8a** and **8b**) were generated from the 2D chemical structures using Open Babel and Balloon [15, 16]. Every 25th conformer for **3** was geometrically optimized in MeOH using the conductor-like polarizable continuum model (CPCM) using the B3LYP/6–31 + G(d,p) level with Grimme dispersion corrections (GD3) [17]. The coupling constants between the vicinal protons at C-1' and C-6' on the cyclohexene ring of the lowest-energy conformers of 1'S-**3** and 1'R-**3** were predicted by the Karplus equation. [18] Every 25th conformer for **7** and **8** was geometrically optimized in the gas phase using the B3LYP/6–31 + G(d,p) level of theory. Every 25th conformer for **7a**, **7b**, **8a**, and **8b** was geometrically optimized in the gas phase using the B3LYP/Def2TZVP level of theory. The ECD calculations for 1'S-**3** and 1'R-**3** were conducted at the CAM-B3LYP/TZVP level of time-dependent density functional theory (TDDFT) in MeOH using CPCM. The ECD calculations for 3'R-**7**, 3'S-**7**, 3'R-**8**, and 3'S-**8** were conducted at the B3LYP/6–31 + G(d,p) level of TDDFT in MeOH using CPCM. ECD calculations for **7a**, **7b**, **8a**, and **8b** were conducted at the B3LYP/TZVP level of TDDFT in MeOH using CPCM. All calculations were performed using Gaussian 16 [19]. The ECD spectra were obtained from 45 calculated excitation energies and rotational strengths as the sum of the Gaussian functions centered at the wavelength of each transition with parameter *s*, which represents the width of the band at a half-height of 0.30 eV.

Cytotoxicity against RAW264.7

The RAW 264.7 murine macrophage cell line was obtained from the American Type Culture Collection (ATCC TIB71, VA, USA). The cells were grown at 37 °C in DMEM medium (FUJIFILM Wako Pure Chemical Corporation, Ltd., Osaka, Japan.) supplemented with 10% FBS (NICHIREI BIOSCIENCES INC., Tokyo, Japan), penicillin (100 units/mL), and streptomycin sulfate (100 mg/mL).

The cytotoxicity of the isolated compounds (**1–9**) was estimated using a cell counting kit-8 (Dojindo Laboratories, Kumamoto, Japan) to count living cells by combining 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazolium (WST-8) with 1-methoxyphenazinemethosulfate (1-methoxy-PMS). RAW264.7 cells were dispensed in 100 µL cell suspensions (5×10^3 cells/well) onto a 96-well plate and preincubated for 2 h in a humidified incubator (37 °C, 5% CO₂). Cells were treated with the isolated compounds (**1–9**) (100 µg/mL) in PBS and compared with a nontreated control group ($n = 3$ wells per group). The treated cells were incubated for 24 h, CCK-8 was added to each well, and the cells were cultured for an additional 2 h. The absorbance of each well was measured at 450 nm using a multi-plate reader (FilterMax F5; Molecular Devices, CA, USA). The ratio of the mean absorbance value for each group to that of the control group was used to determine cell viability.

Inhibitory effects on NO production in LPS-stimulated RAW264.7 cells. RAW 264.7 macrophages were plated at 6.0×10^5 cells/0.5 mL in 24 plates and then incubated with or without LPS (1 µg/mL) in the absence or presence of the isolated compounds (**1–9**) for 24 h. Nitrite accumulation in the culture medium was measured as an indicator of NO production, based on the Griess reaction. Briefly, 80 µL of cell culture medium was mixed with 80 µL of Griess reagent [equal volumes of % (w/v) sulfanilamide in 5% (v/v) phosphoric acid and 0.1% (w/v) naphthylethylenediamine-HCl], incubated at room temperature for 10 min; thereafter, the absorbance was measured at 540 nm in a microplate reader (FilterMax F5). Fresh culture medium was used as the blank for all experiments. The amount of nitrite in each sample was measured using a serially diluted sodium nitrite standard curve.

FAAH inhibitory activity

The FAAH inhibitory activities of all the isolated compounds (**1–9**) were evaluated using a Fatty Acid Amide Hydrolase Inhibitor Screening Assay Kit (Cayman Chemical Company, Michigan, USA). Positive control (JZL195) concentrations were 20 µM, 10 µM, 2 µM, 0.2 µM, 0.02 µM, and 0.002 µM. The inhibitory activity of each compound

(10 mg/mL in DMSO at the time of preparation) was tested using a screening approach. For those showing more than 50% inhibition, diluted samples (1 mg/mL at the time of preparation, dissolved in DMSO, and 0.1 mg/mL at the time of preparation, dissolved in DMSO) were tested and the IC₅₀ value was calculated between the two points when 50% inhibition was between the two points.

In a 96-well plate, 170 µL of 125 mM Tris–HCl containing 1 mM EDTA buffer (pH 9.0), 10 µL of FAAH (human recombinant) solution, and 10 µL of sample solution were added and mixed. Blank wells comprised 180 µL of buffer and 10 µL of DMSO instead of the sample; the positive control wells comprised 10 µL of JZL195 (20 µM at the time of preparation, dissolved in DMSO) instead of the sample, and background wells comprised 10 µL of DMSO instead of FAAH solution. The mixture was incubated at 37 °C for 5 min. Subsequently, 10 µL of FAAH substrate (AMC arachidonoyl amido, 20 µM at the time of preparation, dissolved in EtOH) was added to each well. The wells were incubated again at 37 °C for 30 min. The fluorescence was measured at room temperature, after incubation, using a SpectraMax® iD5 Multimode Microplate Reader (moleculardevices, Tokyo, Japan) at an excitation wavelength of 350 nm and emission wavelength of 460 nm. The inhibition rate was calculated using the following equation: Inhibition rate (%) = $[1 - \{(A_{\text{sample}}) - (A_{\text{background sample}})\} / \{(A_{\text{blank}}) - (A_{\text{background blank}})\}] \times 100$.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s11418-025-01965-9>.

Acknowledgements We thank Dr. S. Sato and Mr. T. Matsuki of Tohoku Medical and Pharmaceutical University for their assistance with the NMR and MS analyses. We would like to thank Mr. Y. Okunuki, Mr. H. Yabe, and Mr. H. Yamashita of Hitachi Seaside Park and all the people involved for providing the *Nemophila menziesii*. We would like to thank Editage (www.editage.com) for the English language editing.

Author Contributions The manuscript was written through the contributions of all authors. All authors have given approval to the final version of the manuscript. NK, YI, TK, KS, and TM: Conceptualization; NK, YI, TK, EI, HS, and TM: Methodology; NK, YI, TK, and TM: Validation and Investigation; NK, YI, TK, EI, HS, KS, and TM: Resources; NK, YI, TK, and TM: Writing – Original Draft; NK, YI, TK, EI, and TM: Visualization; YI, TK, KS, and TM: Supervision.

Funding Open Access funding provided by Tohoku Medical and Pharmaceutical University.

Declarations

Conflict of interest The authors declare no conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source,

provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Tatsuzawa F, Toki K, Ohtani Y, Kato K, Saito N, Honda T, Mii M (2014) Floral pigments from the blue flowers of *Nemophila menziesii* 'insignis blue' and the purple flower of its variants. *J Jpn Soc Hortic Sci* 83:259–266. <https://doi.org/10.2503/jjshs1.CH-100>
2. Fuloria NK, Raheja RK, Shah KH, Oza MJ, Vetrivelan KYA, Subramaniyan MS, Fuloria S (2022) Biological activities of meroterpenoids isolated from different sources. *Front Pharmacol* 13:830103. <https://doi.org/10.3389/fphar.2022.830103>
3. Zeukang RD, Kalinski J-C, Tembeni B, Goosen ED, Tembu J, Kuaiate TT, Bikobo DSN, Fotsing MT, Atchadé AdeT, Siwe-Noundou X (2023) Quinones from *Cordia* species from 1972 to 2023: isolation, structural diversity and pharmacological activities. *Nat Prod Bioprospect* 13:52. <https://doi.org/10.1007/s13659-023-00414-y>
4. Zhao L-H, Yan H-W, Jiang J-S, Zhang X, Yang Y-N, Yuan X, Zhang P-C (2025) Arnebinfuranoids A-G, seven unique heterodimers of meroterpenoids from *Arnebia euchroma*. *Phytochemistry* 235:114461. <https://doi.org/10.1016/j.phytochem.2025.114461>
5. Tanaka T, Nakashima T, Ueda T, Tomii K, Kouno I (2007) Facile discrimination of aldose enantiomers by reversed-phase HPLC. *Chem Pharm Bull* 55:899–901. <https://doi.org/10.1248/cpb.55.899>
6. Garrido L, Zubia E, Ortega MJ, Salva J (2002) New Meroterpenoids from the Ascidian *Aplidium conicum*. *J Nat Prod* 65:1328–1331. <https://doi.org/10.1021/np020176+>
7. Simon-Levert A, Arrault A, Bontemps-Subielos N, Canal C, Banaigs B (2005) Meroterpenes from the ascidian *Aplidium aff. densum*. *J Nat Prod* 68:1412–1415. <https://doi.org/10.1021/np050110p>
8. Lopez G, Witczak A, Menniti C, Inguimbert N, Banaigs B (2012) Rapid synthesis of methoxyconidiol and conitriol stereoisomers. *Tetrahedron Lett* 53:4548–4550. <https://doi.org/10.1016/j.tetlet.2012.06.050>
9. Ren P, Miao X, Tang T, Wu Y, Wang J, Zeng Y, Li Y, Gao K, Yang Y-L (2020) Construction of a meroterpenoid-like compound collection by precursor-assisted biosynthesis. *Org Biomol Chem* 18:5850–5856. <https://doi.org/10.1039/d0ob01235a>
10. Tahir MN, Shahbazi F, Rondeau-Gagné S, Trant JF (2021) The biosynthesis of the cannabinoids. *J Cannabis Res* 3:7. <https://doi.org/10.1186/s42238-021-00062-4>
11. Yadav S, Sharma A, Nayik GA, Cooper R, Bhardwaj G, Sohail HS, Mutreja V, Kaur R, Areche FO, AlOudat M, Shaikh AM, Kovács B, Ahmed AEM (2022) Review of shikonin and derivatives: isolation, chemistry, biosynthesis, pharmacology and toxicology. *Front Pharmacol* 2022:905755. <https://doi.org/10.3389/fphar.2022.905755>
12. Elmes MW, Kaczoch M, Berger WT, Leung KN, Ralph BP, Wang L, Sweeney JM, Miyauchi JT, Tsirka SE, Ojima I, Deutsch DG (2015) Fatty Acid-binding proteins (FABPs) are intracellular carriers for Δ^9 -Tetrahydrocannabinol (THC) and Cannabidiol (CBD). *J Biol Chem* 290:8711–8721. <https://doi.org/10.1074/jbc.M114.618447>
13. Chittenden RJ, Turrill WB (1926) Taxonomic and genetical notes on some species of *Nemophila*. *Bull Miscellan Inf (Royal Botanic Gardens, Kew)* 1926:1–12. <https://doi.org/10.2307/4114316>
14. Ishikawa YA (2013) Script for automated 3-dimensional structure generation and conformer search from 2-dimensional chemical drawing. *Bioinformatics* 9:988–992. <https://doi.org/10.6026/97320630009988>
15. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR (2011) Open babel: an open chemical toolbox. *J Cheminform* 3:33. <https://doi.org/10.1186/1758-2946-3-33>
16. Vainio MJ, Johnson MS (2007) Generating conformer ensembles using a multiobjective genetic algorithm. *J Chem Inf Model* 47:2462–2474. <https://doi.org/10.1021/ci6005646>
17. Grimme S, Antony J, Ehrlich S, Krieg H (2010) A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu. *J Chem Phys* 132:154104. <https://doi.org/10.1063/1.3382344>
18. Navarro-Vazquez A, Cobas JC, Sardina FJ, Casanueva J, Diez E (2004) A graphical tool for the prediction of vicinal proton–proton $^3J_{HH}$ coupling constants. *J Chem Inf Comput Sci* 44:1680–1685. <https://doi.org/10.1021/ci049913t>
19. Gaussian 16, Revision C.01, Frisch M J, Trucks G W, Schlegel H B, Scuseria G E, Robb M A, Cheeseman J R, Scalmani G, Barone V, Petersson G A, Nakatsuji H, Li X, Caricato M, Marenich A V, Bloino J, Janesko B G, Gomperts R, Mennucci B, Hratchian H P, Ortiz J V, Izmaylov A F, Sonnenberg J L, Williams-Young D, Ding F, Lipparini F, Egidi F, Goings J, Peng B, Petrone A, Henderson T, Ranasinghe D, Zakrzewski V G, Gao J, Rega N, Zheng G, Liang W, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Throssell K, Montgomery J A Jr, Peralta J E, Ogliaro F, Bearpark M J, Heyd J J, Brothers E N, Kudin K N, Staroverov V N, Keith T A, Kobayashi R, Normand J, Raghavachari K, Rendell A P, Burant J C, Iyengar S S, Tomasi J, Cossi M, Millam J M, Klene M, Adamo C, Cammi R, Ochterski J W, Martin R L, Morokuma K, Farkas O, Foresman J B, Fox D J Gaussian, Inc., Wallingford CT, (2016)

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Nanami Kurosawa¹ · Yoshinobu Ishikawa² · Tatsuo Katagiri³ · Eri Isowaki⁴ · Hayato Sato⁴ · Kenroh Sasaki¹ · Toshihiro Murata¹ 

✉ Toshihiro Murata
murata-t@tohoku-mpu.ac.jp

¹ Division of Pharmacognosy, Tohoku Medical and Pharmaceutical University, 4-1 Komatsushima 4-Chome Aoba-Ku, Sendai 981-8558, Japan

- ² Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, 16-10 Kamishinano, Totsuka-Ku, Yokohama 244-0806, Japan
- ³ Faculty of Liberal Arts and Sciences, University of Toyama, 2630, Sugitani, Toyama 930-0194, Japan

- ⁴ School of Pharmacy and Pharmaceutical Sciences, University of Toyama, 2630, Sugitani, Toyama, 930-0194, Japan